Welcome to our dedicated page for Aceragen news (Ticker: ACGN), a resource for investors and traders seeking the latest updates and insights on Aceragen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aceragen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aceragen's position in the market.
Summary not available.
Summary not available.
Aceragen, Inc. (Nasdaq: ACGN) announced that its independent Data Monitoring Committee (DMC) recommended the continuation of the TERRA Phase 2 study for ACG-701, targeting melioidosis patients. This recommendation is based on a planned safety review, allowing the trial to proceed without modifications. The TERRA study, which began in May 2022, is a randomized double-blind trial aimed at evaluating ACG-701's effectiveness in severely ill patients. The company has secured a development partnership worth approximately $50 million with the Department of Defense to explore ACG-701 as a medical countermeasure. Data read-out from the study is expected in Q4 2023.
